The Canadian government has barred Teva Pharmaceuticals USA, the American arm of the global generic drug manufacturer Teva Pharmaceuticals, from entering into federal contracts until spring 2025. This decision is a consequence of the company’s involvement in a “domestic antitrust cartel” in the United States, leading to a US$225-million criminal penalty.
Featured News
South Korean Steelmaker POSCO Expands Supplier Support Pact With Antitrust Regulator
Jul 16, 2026 by
CPI
FCC’s Carr Criticizes California-Led Bid to Block Paramount-Warner Bros. Discovery Deal
Jul 16, 2026 by
CPI
EU Top Court Upholds Antitrust Powers to Seize Corporate Emails
Jul 16, 2026 by
CPI
Uber Launches $14.8 Billion Bid for Delivery Hero in Landmark Food Delivery Deal
Jul 16, 2026 by
CPI
EU Orders Google to Open Android and Search Data to Rival AI Services
Jul 16, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Agentic AI & Antitrust
Jul 16, 2026 by
CPI
AI Agents and Collusion: The Two Faces of Agentic AI
Jul 16, 2026 by
Giovanna Massarotto
Agentic AI’s Regulatory Conundrum
Jul 16, 2026 by
Anant Raut
Inter-AI-Agent Competition
Jul 16, 2026 by
Stefan Thomas
Navigating the Increasing Regulatory Scrutiny of AI-Pricing Tools: Competition and Other Emerging Risks
Jul 16, 2026 by
Mark Krotoski & Vinny Sidhu